# Pathios Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pathios-therapeutics

- Industry: Biotechnology
- Headquarters: Abingdon, UK
- Website: www.pathiostherapeutics.com
- Total disclosed funding: $34M
- Latest round: Series B (Apr 18, 2024)
- Investors on record: 3

## About

Based in Oxford, UK, and founded in 2017 by co-founders Tom McCarthy and Stuart Hughes, Pathios Therapeutics Limited operates as a biotechnology company that engages in research and development of immunotherapy approach for cancers. In April 2024, Pathios Therapeutics Limited raised USD 25 million in Series B funding led by Bristol-Myers Squibb Company, with participation from Canaan Partners and Brandon Capital Partners. 

Pathios Therapeutics Limited provides oncology and immunology solutions for cancer treatment through targeting the acid sensing GPCR, GPR65. The company’s product, PTT-4256, is an orally bioavailable, highly potent, and selective GPR65 inhibitor, designed to reverse the immunosuppressive effects of acidic pH in the TME. It developed human genetics-led research, transcriptomics, and cellular immunology with insights into the underlying causal biology of immune cell dysfunction in cancer. The company's research extends beyond cancer, exploring the potential of GPR65 modulation in other immunological diseases like Inflammatory Bowel Disease and Multiple Sclerosis.

## Funding rounds

- Series B, Apr 18, 2024, $25M — Canaan Partners, Brandon Capital Partners, Bristol-Myers Squibb Company
- Series A, Sep 9, 2019, $8.8M — Canaan Partners, Brandon Capital Partners

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series A, Series B
- Bristol-Myers Squibb Company — Series B